Pancreatic safety of sodium‐glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis

This study aimed to systematically evaluate the association between sodium‐glucose cotransporter 2 (SGLT2) inhibitors and pancreatic safety in patients with type 2 diabetes mellitus (T2DM).

• Publication year

  2020

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2020-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pds.4943PMID 32017292
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial

  2019cited by this paper
• Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

  2019cited by this paper
• Empagliflozin-Induced Pancreatitis

  2018cited by this paper
• Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

  2018cited by this paper
• Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial

  2018cited by this paper
• Dapagliflozin Induced Pancreatitis

  2018cited by this paper
• Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

  2018cited by this paper
• Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials.

  2018cited by this paper
• Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

  2018cited by this paper
• Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

  2018cited by this paper
• A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study

  2018cited by this paper
• Sodium‐glucose co‐transporter‐2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta‐analysis of randomized controlled trials

  2017cited by this paper
• SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials

  2017cited by this paper
• Drug-Induced Necrotizing Pancreatitis With a Focus on Canagliflozin.

  2017cited by this paper
• Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials

  2017cited by this paper
• Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017influential reference
• Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials

  2017cited by this paper
• Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

  2017cited by this paper
• Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

  2016cited by this paper
• Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

  2016cited by this paper
• Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

  2016cited by this paper
• Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes

  2016cited by this paper
• Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.

  2016cited by this paper
• Acute Pancreatitis.

  2016cited by this paper
• Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta‐analysis of randomized controlled trials

  2016cited by this paper
• Canagliflozin-Associated Acute Pancreatitis

  2016cited by this paper
• Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

  2015influential reference
• Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

  2015cited by this paper
• Canagliflozin-induced pancreatitis: a rare side effect of a new drug

  2015cited by this paper
• Functional expression of sodium-glucose transporters in cancer

  2015cited by this paper
• Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes

  2015cited by this paper
• Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus

  2015cited by this paper
• Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015influential reference
• Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes

  2015influential reference
• Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.

  2014influential reference
• Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

  2014cited by this paper
• Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

  2014cited by this paper
• Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

  2014cited by this paper
• Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.

  2014cited by this paper
• Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

  2014cited by this paper
• Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial

  2014cited by this paper
• Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

  2014influential reference
• A Review on the Relationship between SGLT2 Inhibitors and Cancer

  2014cited by this paper
• Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

  2014influential reference
• Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

  2014influential reference
• Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

  2014cited by this paper
• Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials

  2014influential reference
• Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

  2014cited by this paper
• Contemporary review of drug-induced pancreatitis: A different perspective.

  2014cited by this paper
• Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

  2013cited by this paper
• Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis

  2013cited by this paper
• Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

  2013cited by this paper
• Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

  2013cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration

  2013cited by this paper
• Drug-Induced Pancreatitis

  2012cited by this paper
• SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

  2012cited by this paper
• Critical interpretation of Cochran's Q test depends on power and prior assumptions about heterogeneity

  2010cited by this paper
• Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Chapter 8: Assessing risk of bias in included studies

  2008cited by this paper
• Expression of SGLT1, Bcl-2 and p53 in Primary Pancreatic Cancer Related to Survival

  2008cited by this paper
• Drug-induced acute pancreatitis: an evidence-based review.

  2007cited by this paper
• Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events

  2007cited by this paper
• Trends in the Epidemiology of the First Attack of Acute Pancreatitis: A Systematic Review

  2006cited by this paper
• [Acute pancreatitis].

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Pancreatitis and the risk of pancreatic cancer.

  1993cited by this paper
• The efficacy of phloridzin and phloretin on tumor cell growth.

  1993cited by this paper

• Obesity, type 2 diabetes and cancers of the digestive system.

  2026cites this paper
• Risk of acute pancreatitis with DPP-4 inhibitors versus SGLT2 inhibitors in medication-naïve individuals with diabetes: A target trial emulation.

  2026cites this paper
• Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study.

  2025cites this paper
• A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors

  2025cites this paper
• Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk.

  2025cites this paper
• New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: a nationwide population-based cohort study.

  2025cites this paper
• Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety study

  2024cites this paper
• Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study.

  2023cites this paper
• Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin

  2023cites this paper
• SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports

  2022cites this paper
• The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management

  2022cites this paper
• Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: a propensity score-matched study with competing risk analysis

  2022cites this paper
• Pancreas and Adverse Drug Reactions: A Literature Review

  2022cites this paper
• Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database

  2022cites this paper
• Obesity, diabetes mellitus, and pancreatic carcinogenesis: Correlations, prevention, and diagnostic implications.

  2022cites this paper
• Is there a relationship between gliflozins and acute pancreatitis? Evidence-based analysis

  2022cites this paper
• Pancreaticopleural fistula: An insidious cause of pleural effusion –case report

  2021cites this paper
• An investigation on the association between sodium glucose co‐transporter 2 inhibitors use and acute pancreatitis: A VigiBase study

  2021cites this paper
• SGLT2 inhibitors for type 2 diabetes mellitus in adults: an overview of forty-six systematic reviews.

  2021cites this paper
• SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Diabetes bei chronischer Pankreatitis

  2021cites this paper
• Treatment of type 2 diabetes mellitus and risk of pancreatic cancer.

  2021cites this paper
• Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development

  2021cites this paper
• Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study

  2020cites this paper
• Safety and efficacy of pharmacologic weight loss in patients with cirrhosis

  2020cites this paper
• Pancreatitis or pancreatic cancer with SGLT2 inhibitors

  2020cites this paper